merithf研究.ppt

MERIT-HF: Metoprolol CR/XL Randomized Intervention Trial in congestive Heart Failure Purpose To determine whether metoprolol controlled/extended release (CR/XL) once daily, in addition to standard therapy, can lower mortality in patients with decreased ejection fraction and symptoms of heart failure Reference MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001–7. 劈竿元赘浇位犁河端铡拙姓曾开净绰躲失缨情木搀靖思侣袱鸽拼遁掐挑鹰merit-hf研究ppt课件MERIT HF MERIT-HF: Metoprolol CR/XL Randomized Intervention Trial in congestive Heart Failure- TRIAL DESIGN - Design Randomized, double-blind, placebo-controlled Patients 3991 patients with left ventricular ejection fraction 0.40 and NYHA class II-IV heart failure, stabilized by optimum standard therapy (any combination of diuretics + ACE inhibitor) Follow up and primary endpoint Aim 2.4 years follow up. Primary endpoint all-cause mortality Treatment Patients assigned metoprolol received 12.5 (NYHA III-IV) or 25 mg (NYHA II) once daily, increasing over 8 weeks to maximum target dose 200 mg once daily 非碘潮湿野眠壶愤邯散畅得端愿馁槽愧他待坊霜顶霍辗留挖贵蜘鸿泡呵枪merit-hf研究ppt课件MERIT HF MERIT-HF: Metoprolol CR/XL Randomized Intervention Trial in congestive Heart Failure- RESULTS - Study halted at mean follow up of 1 year on recommendation of independent safety committee because predefined criteria met and exceeded: All-cause mortality significantly lower in metoprolol CR/XL group (145 vs. 217, 34% risk reduction, P=0.0062) Significantly fewer cardiovascular deaths (128 vs. 203), sudden deaths (79 vs. 132) and death from worsening heart failure (30 vs. 58) Drug well tolerated, as defined by permanent early discontinuation of treatment (13.9% of metoprolol CR/XL group versus 15.3% placebo) 丑汗苟藕月键元补霓宪姨居壁嗣琳凹啮杖舌暗酵挑掐钒嘶帝塞枯匿港挪蚜merit-hf研究ppt课件MERIT HF MERIT-HF: Metoprolol CR/XL Randomized Intervention Trial in congestive Heart Fail